This inventor holds 1 USPTO granted patent and 3 published patent applications and 6 EPO patents. Top assignee: Ascendis Pharma A/s. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Lars Holten-Andersen: Innovator in Drug Delivery Systems
Introduction
Lars Holten-Andersen is a notable inventor based in Hellerup, Denmark. He has made significant contributions to the field of drug delivery systems, particularly in the area of controlled-release formulations. Although he currently holds no granted patents, his work in pharmaceutical innovation is noteworthy.
Latest Patent Applications
Lars Holten-Andersen has filed several patent applications that focus on advanced drug delivery mechanisms. One of his latest applications is titled "Sustained Local Drug Levels for Innate Immune Agonists." This invention relates to a water-insoluble controlled-release pattern recognition receptor agonist (PRRA) or its pharmaceutically acceptable salt. The application emphasizes the treatment of cell-proliferation disorders through intra-tissue administration, ensuring that at least 25% of the PRRA remains localized in the tissue for three days post-administration. Another significant application is "Induction of Sustained Local Inflammation," which also involves a water-insoluble controlled-release PRRA. This invention aims to treat cell-proliferation disorders by inducing local inflammation through intra-tissue administration.
Conclusion
Lars Holten-Andersen's innovative approaches in drug delivery systems highlight his commitment to advancing pharmaceutical science. His latest patent applications reflect a focus on improving treatment efficacy through controlled-release mechanisms.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile